Late Breaking Abstract on DRX-065 in Mouse Models of NASH at the Liver Meeting 2016

21/10/2016  12:50

Sheila DeWitt (President and CEO of DeuteRx, Andover, MA, USA) will be presenting a late breaking abstract/poster on the effects of DRX-065 in mouse models of NASH at the Liver Meeting 2016 to be held at the John B. Hynes Veterans Memorial Convention Center, Boston, MA, USA, 11-15 November, 2016. This is the annual meeting of the American Association for the Study of Liver Diseases (AASLD). 

Details of the abstract are:

Sharon C Cheetham, Sheila H DeWitt, Keith Dickinson, Vincent Jacques, Lex H Van der Ploeg and Steven Vickers. Efficacy of DRX-065, the stabilized R-enantiomer of pioglitazone (pio), in choline-deficient (CD) and methionine/choline deficient (MCD) diet mouse models of nonalcoholic steatohepatitis (NASH). LB-32. (Hepatology, Volume 64, Number 6 (Suppl): 1137A).

The study was performed by RenaSci. The MCD and CD diets induce changes in liver enzymes, liver lipids and liver pathology, consistent with the development of NASH. The MCD diet produces marked weight-loss. The CD diet produces a much smaller decrease in body weight compared to mice on normal diet and therefore has a clear advantage over the MCD diet.

Pioglitazone has been shown to improve NASH and fibrosis scores and to reduce hepatic triglycerides in clinical trials for the treatment of NASH. However, its use is limited by its side-effects of weight gain and oedema. Pioglitazone is a mixture of R- and S-enantiomers which chemically interconvert. DRX-065, the deuterium-stabilized R-enantiomer of pioglitazone, has the potential to treat NASH without the undesirable fluid retention and weight gain associated with pioglitazone. The results of the studies in mice maintained on the CD and MCD diets support the development of DRX-065 for the treatment of NASH.

The late-breaking abstracts for the Liver Meeting are now available online. Please click here

For further information about DRX-065, which is in clinical development, please contact Dr Sheila DeWitt at

For further information about our CD and MCD diet mouse models of NASH please contact